Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 475 of 1475 entries
View as:

Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation

Phase: N/A Priority: Normal
NCT ID: NCT03087487 Org: User:
Start: 06/01/16 End: 03/08/23 Due: 03/08/24

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Phase: N/A Priority: Normal
NCT ID: NCT04196452 Org: User:
Start: 08/12/19 End: 06/30/34 Due: 06/30/35

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase: N/A Priority: Normal
NCT ID: NCT02231749 Org: User:
Start: 10/16/14 End: 03/21/25 Due: 03/21/26

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase: N/A Priority: Normal
NCT ID: NCT06646276 Org: User:
Start: 02/25/25 End: 09/05/31 Due: 09/05/32

A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05779592 Org: User:
Start: 11/23/22 End: 09/30/27 Due: 09/30/28

Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir

Phase: N/A Priority: Normal
NCT ID: NCT02532673 Org: User:
Start: 08/31/14 End: 05/31/15 Due: 05/31/16

Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen

Phase: N/A Priority: Normal
NCT ID: NCT00135369 Org: User:
Start: 09/30/02 End: 07/31/05 Due: 07/31/06

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00385580 Org: User:
Start: 01/31/07 End: 10/31/10 Due: 10/31/11

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02638948 Org: User:
Start: 02/16/16 End: 05/03/18 Due: 05/03/19

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01592370 Org: User:
Start: 08/02/12 End: 07/09/24 Due: 07/09/25

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02659059 Org: User:
Start: 02/15/16 End: 03/07/22 Due: 03/07/23

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Phase: N/A Priority: Normal
NCT ID: NCT00859053 Org: User:
Start: 03/31/09 End: 09/30/09 Due: 09/30/10

Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT00110422 Org: User:
Start: 11/30/05 End: 02/28/07 Due: 02/28/08

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Phase: N/A Priority: Normal
NCT ID: NCT03058822 Org: User:
Start: 01/25/17 End: 03/30/17 Due: 03/30/18

Taste Properties of Atazanavir and Cobicistat

Phase: N/A Priority: Normal
NCT ID: NCT02307656 Org: User:
Start: 12/12/14 End: 09/09/21 Due: 09/09/22

A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00719225 Org: User:
Start: - End: - Due: -

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Phase: N/A Priority: Normal
NCT ID: NCT02671461 Org: User:
Start: 04/25/16 End: 03/31/17 Due: 03/31/18

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Phase: N/A Priority: Normal
NCT ID: NCT02769078 Org: User:
Start: 11/30/14 End: 02/29/16 Due: 02/28/17

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Phase: N/A Priority: Normal
NCT ID: NCT00978731 Org: User:
Start: 12/31/05 End: 09/30/08 Due: 09/30/09

Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan

Phase: N/A Priority: Normal
NCT ID: NCT02402699 Org: User:
Start: 12/15/15 End: 03/23/17 Due: 03/23/18

Crossover Post-herpetic Neuralgia (PHN)

Phase: N/A Priority: Normal
NCT ID: NCT01305538 Org: User:
Start: 03/31/11 End: 06/30/12 Due: 06/30/13

Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT03016325 Org: User:
Start: 01/13/17 End: 11/12/19 Due: 11/12/20

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00289627 Org: User:
Start: 04/30/06 End: 07/31/07 Due: 07/31/08

Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT07024862 Org: User:
Start: 10/24/24 End: 06/30/25 Due: 06/30/26

A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography

Phase: N/A Priority: Normal
NCT ID: NCT00767325 Org: User:
Start: 12/31/08 End: 10/31/11 Due: 10/31/12